← Evidence map

ArticleThoracic cancer2020

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.

Weixian HuPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy. | OpenQuestion